Literature DB >> 25573634

[¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.

Clemens Kratochwil1, Frederik L Giesel, Matthias Eder, Ali Afshar-Oromieh, Martina Benešová, Walter Mier, Klaus Kopka, Uwe Haberkorn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25573634     DOI： 10.1007/s00259-014-2978-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.

Authors:  G L Wright; C Haley; M L Beckett; P F Schellhammer
Journal:  Urol Oncol       Date:  1995 Jan-Feb       Impact factor: 3.498

2.  Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.

Authors:  Christian M Zechmann; Ali Afshar-Oromieh; Tom Armor; James B Stubbs; Walter Mier; Boris Hadaschik; John Joyal; Klaus Kopka; Jürgen Debus; John W Babich; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-28       Impact factor: 9.236

3.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Authors:  Shawn M Hillier; Kevin P Maresca; Frank J Femia; John C Marquis; Catherine A Foss; Nghi Nguyen; Craig N Zimmerman; John A Barrett; William C Eckelman; Martin G Pomper; John L Joyal; John W Babich
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

4.  Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

Authors:  H Liu; A K Rajasekaran; P Moy; Y Xia; S Kim; V Navarro; R Rahmati; N H Bander
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

5.  Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Authors:  Ali Afshar-Oromieh; Christian M Zechmann; Anna Malcher; Matthias Eder; Michael Eisenhut; Heinz G Linhart; Tim Holland-Letz; Boris A Hadaschik; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236
  5 in total
  48 in total

1.  [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Authors:  Xing Yang; Ronnie C Mease; Mrudula Pullambhatla; Ala Lisok; Ying Chen; Catherine A Foss; Yuchuan Wang; Hassan Shallal; Hannah Edelman; Adam T Hoye; Giorgio Attardo; Sridhar Nimmagadda; Martin G Pomper
Journal:  J Med Chem       Date:  2015-12-16       Impact factor: 7.446

2.  (68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.

Authors:  Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03       Impact factor: 9.236

3.  The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.

Authors:  Lorenza Scarpa; Sabine Buxbaum; Dorota Kendler; Katharina Fink; Jasmin Bektic; Leonhard Gruber; Clemens Decristoforo; Christian Uprimny; Peter Lukas; Wolfgang Horninger; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-12       Impact factor: 9.236

4.  (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

Authors:  Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-15       Impact factor: 9.236

5.  First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT.

Authors:  Frederik A Verburg; Thomas Krohn; Alexander Heinzel; Felix M Mottaghy; Florian F Behrendt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-28       Impact factor: 9.236

6.  Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.

Authors:  Melanie Hohberg; Wolfgang Eschner; Matthias Schmidt; Markus Dietlein; Carsten Kobe; Thomas Fischer; Alexander Drzezga; Markus Wild
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

7.  Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.

Authors:  Christoph Berliner; Milena Tienken; Thorsten Frenzel; Yuske Kobayashi; Annabelle Helberg; Uve Kirchner; Susanne Klutmann; Dirk Beyersdorff; Lars Budäus; Hans-Jürgen Wester; Janos Mester; Peter Bannas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-28       Impact factor: 9.236

Review 8.  Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.

Authors:  Shankar Siva; Cristian Udovicich; Ben Tran; Homi Zargar; Declan G Murphy; Michael S Hofman
Journal:  Nat Rev Urol       Date:  2020-01-14       Impact factor: 14.432

Review 9.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

10.  Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.

Authors:  Levent Kabasakal; Mohammad AbuQbeitah; Aslan Aygün; Nami Yeyin; Meltem Ocak; Emre Demirci; Turkay Toklu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-31       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.